Equities

Intelligent Bio Solutions Inc

Intelligent Bio Solutions Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.51
  • Today's Change0.03 / 2.03%
  • Shares traded85.13k
  • 1 Year change-64.47%
  • Beta4.7091
Data delayed at least 15 minutes, as of Oct 08 2024 20:39 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Intelligent Bio Solutions Inc. is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its segment includes Commercially available Intelligent Fingerprinting Products and Development Stage Biosensor Platform Technology. Its product portfolio includes Intelligent Fingerprinting Platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader, and a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Biosensor Platform is designed to detect multiple biological analytes by substituting the top enzyme layer of the biosensor to suit each analyte and to develop a range of Point of Care Tests, including the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology.

  • Revenue in USD (TTM)3.11m
  • Net income in USD-10.16m
  • Incorporated2016
  • Employees13.00
  • Location
    Intelligent Bio Solutions Inc135 W 41St St,, Floor 5NEW YORK 10036United StatesUSA
  • Phone+1 (646) 233-6971
  • Fax+1 (302) 575-1642
  • Websitehttps://ibs.inc/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Galmed Pharmaceuticals Ltd0.00-5.88m5.89m3.00--0.1758-----24.68-24.680.0022.250.00----0.00-44.20-45.06-52.67-50.79------------0.00------61.31------
NLS Pharmaceutics AG0.00-12.17m5.97m3.00---------12.75-12.750.00-10.900.00----0.00-218.86-272.62---------------81.34--------26.21------
Adial Pharmaceuticals Inc0.00-12.19m6.08m4.00--0.9536-----5.26-5.300.000.99610.00----0.00-279.27-182.35-320.96-235.45-----------14.250.00------35.14------
Enzolytics Inc0.00-119.19k6.22m2.00---------0.106-0.1060.00-1.040.00-------369.52-----------------4.30-----100.00---9.35------
Xenetic Biosciences Inc2.52m-4.70m6.24m4.00--0.8374--2.48-3.05-3.051.644.830.2314----630,087.50-43.12-48.91-48.61-52.82-----186.33-682.42----0.00--48.80--36.90------
CeCors Inc-100.00bn-100.00bn6.24m6.00---------------0.0163------------------------------------22.70------
Cardio Diagnostics Holdings Inc39.14k-8.77m6.41m7.00--1.59--163.87-0.4899-0.48990.00210.13190.0073--9.135,591.43-163.16---268.73-------22,414.13-----9.320.0295--1,696.84---79.72------
Intelligent Bio Solutions Inc3.11m-10.16m6.50m13.00--0.6348--2.09-39.72-39.722.312.410.25791.928.60239,366.90-84.45-71.59-156.10-144.3645.81---327.50-565.481.42--0.0592--147.58596.394.47------
TFF Pharmaceuticals Inc1.20m-19.39m6.52m19.00--1.04--5.42-7.95-7.950.46591.810.1043--3.5163,293.68-168.10-79.57-212.66-83.41-----1,612.04-8,687.66----0.00--48.01--33.13------
ABVC Biopharma Inc136.40k-11.37m6.67m16.00--0.7808--48.93-1.78-1.780.01720.68820.0114--0.42138,525.00-99.79-103.38-197.79-231.54-24.1176.25-8,762.13-2,019.89---2.500.1873---84.2885.3935.97------
Cannabis Bioscience Internatnl Hlgs Inc56.94m6.94m6.78m389.000.00120.00010.7350.11910.53280.53284.294.920.591762.811.45146,384.307.83--11.73--31.96--13.24--0.685650.750.0631--12.79--177.84------
Viaderma Inc17.80m2.31m6.79m75.000.00030.000021.250.381216.8416.84129.62255.590.412624.691.21237,331.305.36--6.53--28.90--12.99--2.075.660.1718---29.15---40.70------
Organovo Holdings Inc73.00k-13.99m7.04m12.00--0.9879--96.38-1.39-1.390.00690.46350.006--0.74113,650.00-115.47-54.25-136.97-58.4250.68---19,160.27-1,890.163.38--0.00---70.54-48.7815.00---11.87--
Cyclerion Therapeutics Inc0.00-10.47m7.05m1.00--0.7448-----4.261.270.003.490.00----0.00-103.82-72.70-150.23-86.96-------2,565.62----0.00---100.00--30.98------
Alzamend Neuro Inc0.00-7.39m7.16m4.00---------10.69-10.690.00-1.410.00----0.00-344.10-177.86---257.81-----------363.62--------33.14------
Data as of Oct 08 2024. Currency figures normalised to Intelligent Bio Solutions Inc's reporting currency: US Dollar USD

Institutional shareholders

18.92%Per cent of shares held by top holders
HolderShares% Held
Alyeska Investment Group LPas of 31 Mar 2024206.20k6.62%
Hudson Bay Capital Management LPas of 31 Mar 2024108.25k3.47%
Heights Capital Management, Inc.as of 31 Mar 2024108.25k3.47%
Adar1 Capital Management LLCas of 31 Mar 2024108.25k3.47%
Geode Capital Management LLCas of 30 Jun 202419.06k0.61%
The Vanguard Group, Inc.as of 31 Mar 202415.49k0.50%
Citadel Securities LLCas of 31 Mar 202414.84k0.48%
Citigroup Global Markets, Inc. (Investment Management)as of 31 Mar 20247.96k0.26%
Tower Research Capital LLCas of 31 Mar 20241.05k0.03%
UBS Securities LLCas of 31 Mar 2024348.000.01%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.